Influenza

PIP Framework Governance

The PIP Framework has a three-pronged governance structure:

  • The World Health Assembly which oversees the Framework's implementation;
  • The Director-General who promotes implementation of the Framework and advises the World Health Assembly; and,
  • The PIP Framework Advisory Group that monitors the implementation of the PIP Framework and provides guidance to the Director-General.

This page contains information on the governance of the PIP Framework, including the Secretariat's efforts to implement decisions of the World Health Assembly and recommendations of the PIP Advisory Group.

The Advisory Group (AG) is a group of 18 independent technical experts who monitor the PIP Framework and advise the WHO Director-General on its functioning.

The PIP AG meets twice each year in Geneva to monitor developments and to provide recommendations to the Director-General. More information on the PIP Advisory Group, including its Members, Reports, and work in various technical areas is available at the link below.

The World Health Assembly (WHA) is the decision-making body of WHO, which oversees the implementation of the PIP Framework. The Executive Board is a group of 34 members which, among other tasks, agrees on the agenda for, and resolutions to be considered by, the WHA.

The PIP Secretariat and PIP Advisory Group regularly report to the WHA and to the EB. In addition, the WHA and EB have adopted a number of decisions and resolutions relevant to the PIP Framework. These documents are available at the link below.

Decision WHA72(12) (2019)

At the Seventy-Second World Health Assembly in May 2019, Member States adopted Decision WHA72(12), which made a number of requests to the Director-General related to, among other things, influenza virus sharing, genetic sequence data, and the Standard Material Transfer Agreement 2 (SMTA2). WHO's work to implement this Decision is described at the following link:

Implementation of Decision WHA72(12)

Decision WHA70(10) (2017) (Seasonal Influenza & GSD)

At the request of the Seventieth World Health Assembly (2017) the Director-General conducted an Analysis of the implications of pursuing or not pursuing possible approaches to seasonal influenza viruses and GSD under the PIP Framework. The Analysis, along with accompanying information, is available at the following link:

Genetic sequence data (GSD) are the order of nucleotides found in a molecule of DNA or RNA. They contain the genetic information that determines the biological characteristics of an organism or a virus. In the case of influenza viruses, this can include characteristics such as pathogenicity, transmissibility and antiviral susceptibility.

GSD derived from influenza viruses with human pandemic potential (IVPP) are included under the PIP Framework, but not in the definition of PIP BM. While access to physical viruses (PIP BM) requires signing an SMTA2 and is linked to payment of the Partnership Contribution, access to IVPP GSD is only linked to payment of the Partnership Contribution.

PIP Advisory Group's work on GSD

    PIP Framework section 5.2.4 requests the Director-General to consult with the PIP Advisory Group on the best process for further discussion and resolution of issues related to the handling of the genetic sequence data (GSD) of influenza viruses with pandemic potential, under the Framework.
  • PIP Advisory Group's work on GSD

Analysis of Seasonal Influenza and GSD

    At the request of the Seventieth World Health Assembly (2017), the Director-General conducted an Analysis of the implications of pursuing or not pursuing possible approaches to seasonal influenza viruses and GSD under the PIP Framework. The Analysis, along with accompanying information, is available at the following link:
  • Analysis of Seasonal & GSD - Home Page

In 2016 the PIP Framework underwent its first comprehensive review. A group of 8 independent experts was convened to assess what the PIP Framework had achieved so far, and what were the challenges and possible ways of addressing them.

The Review Group began its work in January 2016 and provided its final report in October 2016, for transmission to the 142nd Executive Board in January 2017.